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Abstract: Genomic analysis and digitalization of medical records have led to a big data scenario
within hematopathology. Artificial intelligence and machine learning tools are increasingly used to
integrate clinical, histopathological, and genomic data in lymphoid neoplasms. In this study, we
identified global trends, cognitive, and social framework of this field from 1990 to 2020. Metadata
were obtained from the Clarivate Analytics Web of Science database in January 2021. A total of
525 documents were assessed by document type, research areas, source titles, organizations, and
countries. SciMAT and VOSviewer package were used to perform scientific mapping analysis.
Geographical distribution showed the USA and People’s Republic of China as the most productive
countries, reporting up to 190 (36.19%) of all documents. A third-degree polynomic equation
predicts that future global production in this area will be three-fold the current number, near 2031.
Thematically, current research is focused on the integration of digital image analysis and genomic
sequencing in Non-Hodgkin lymphomas, prediction of chemotherapy response and validation of
new prognostic models. These findings can serve pathology departments to depict future clinical
and research avenues, but also, public institutions and administrations to promote synergies and
optimize funding allocation.
Keywords: artificial intelligence; hematopathology; lymphoid neoplasms; digital image analysis;
machine learning
1. Introduction
The storage of clinical information in the electronic medical record and the incorpo-
ration of omics data (genomic, transcriptomic, and proteomic) into the patient’s history
have led to a novel scenario within pathology departments. Currently, large volumes of
information are available for investigators and clinicians, who need to process, integrate,
and translate them into daily medical practice.
This data-driven paradigm of 4P medicine (predictive, personalized, preventive,
and participative) [1] requires the implementation of computer systems able to process
this huge amount of clinical information. In this setting, artificial intelligence (AI) and
machine learning (ML) tools have the potential to meliorate diagnostic precision and
improve prediction accuracy, and, thus, contribute to a better planification of personalized
therapeutic strategies [2].
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In recent years, several countries have made public their national research, develop-
ment, and innovation (RDI) strategies in AI [3–5]. The European Union (EU) [6], the United
States of America (USA) [7–9], and the United Kingdom (UK) [10,11] have communicated
their plans for economic coordination in AI and, specifically, an investment increase of
20 billion euros per year is foreseen until 2027 in the EU to develop its coordinated strategy
in AI [6].
Among medical disciplines, the field of hematopathology has been pioneering in
the application of novel methodologies into the clinical setting, leading to milestones in
translational cancer research, such as molecular targeted therapies in chronic myeloid
leukemia and acute promyelocytic leukemia, which have rendered curable diseases once
considered fatal [12,13].
Regarding this, several works have reported the crescent use of AI and ML tools in the
diagnosis of hematological diseases [14,15]. Among hematological malignancies, lymphoid
neoplasms (LN) constitute one of the most active foci of research in this area, and different
AI algorithms have been developed to improve accuracy in lymphoma subtyping [16,17],
validation of prognostic models [18], and prediction of chemotherapy response [19,20].
However, a global analysis of the major trends, leading producers, and scientific mapping
of AI and ML applications to diagnostic pathology in LN has not yet been undertaken.
In this study, we evaluated AI and ML applications in LN through bibliometric tech-
niques. Documental evolution, prediction on future production, and leading research
centers and countries were identified. Furthermore, we performed scientific mapping
analysis (SMA) by means of the packages SciMAT (Science Mapping Analysis Software
Tool) [21] and VOS (Visualizing Of Science) viewer [22] to longitudinally assess the cogni-
tive framework and social structure of this research field.
2. Materials and Methods
2.1. Sample
The metadata used in the study were obtained from the Clarivate Analytics Web
of Science (WoS) core collection database of the Thomson Reuters Institute for Scientific
Information (ISI) (Philadelphia, PA, USA). Documents were retrieved by searching ((“ar-
tificial intelligence” or “deep learning” or “machine learning” or “neural network” or
“support vector” or “natural language”) and (“lymphoid neoplasm” or lymphoma or
lymphoproliferative or lymphocytic or gammopathy or myeloma or histiocytic)) as topics
in the SCI-Expanded Collection for a period range from 1990 to 2020. The dataset was
extracted in January 2021 and downloaded in a tab delimited TXT format.
WoS provides information for more than 250 disciplines and, when performing bib-
liometric analysis, citation data availability is considered one of its main advantages in
comparison with other scientific databases such as MedLine [23,24]. Additionally, because
of its wide use among the biomedical community, and to evaluate the consistence of our
query, we also tested it in PubMed, filtering by article type (journal articles and reviews),
subject (cancer; neither AIDS nor complementary medicine), journal (MEDLINE; neither
dental journals nor nursing journals), and for the same period (1990–2020). A total of
528 documents was obtained, and we could confirm homogeneity in the retrieved results.
2.2. Performance Analysis
Obtained results were classified by document type and then, analysis by research areas,
source titles, organizations, and countries was performed on original articles, reviews,
proceeding papers, and meeting abstracts, by excluding other minor types such as letters,
book chapters, and editorial material.
2.3. Science Mapping Analysis (SMA)
SciMAT (Version 1.1.04., University of Granada, Granada, Spain, License GPLv3) and
VOS Viewer (Version 1.6.16., Centre for Science and Technology Studies, Leiden University,
Leiden, The Netherlands) software were used to perform SMA. In order to achieve a better
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comprehension of the development of the research field, the analysis was performed for the
subperiods: (1) 1990–2005, (2) 2006–2014, and (3) 2015–2020, allowing for a homogeneous
distribution of documents.
2.3.1. SMA for Cognitive Framework
SciMAT was employed to longitudinally evaluate the cognitive framework of the
area, as previously reported [24]. Briefly, SciMAT uses the author’s keywords (AK) of each
article to construct a co-occurrence matrix (CM). Each significant concept (or theme) is
defined as the group of AK employed by different researchers during the period analyzed.
At this point, the simple center algorithm is applied to construct a thematic network from
the CM previously defined. Consequently, the volume of the spheres shown in the strategic
diagram is proportional to the number of published articles that contain this specific notion.
Regarding the sources used to construct these strategic diagrams with SciMAT, the
package employs the files containing the bibliometric information required, that is, the set
of keywords included in each document within the dataset, as it is retrieved from WoS
after performing the query term above mentioned. In this sense, a co-occurrence of two
keywords during the process of analysis is defined as the joint appearance of two keywords
in the same document, as originally conceived by Callon et al. in the seminal papers which
laid the foundations of co-word analysis [25,26]. In this study, we employed the simple
center algorithm to perform this task, but other approaches were also described such as
the single-linkage or sum-linkage [27,28]. Nevertheless, the simple center algorithm has
also been validated and employed to identify, characterize, and visualize the cognitive
evolution of scientific research in other disciplines [23].
Once these concepts (themes) are obtained, a two-dimensional strategic diagram is
depicted based on Callon´s centrality and Callon´s density [25]. These parameters allow a
research field to be comprehended as a set of research themes, and SciMAT enabled us to
map them into four groups:
(a) Motor themes (MT): Present a high density and a strong centrality signifying the most
developed themes for the research area studied (upper-right quadrant);
(b) Basic and transversal themes (BT): Represent themes shared for several disciplines;
thus, their foundations are well-established (lower-right quadrant);
(c) Emerging or declining themes (ED): Have a weak density and a low centrality and,
thus, represent marginal areas of knowledge (lower-left quadrant);
(d) Highly developed or isolated themes (HDI): Show a high density, meaning a signifi-
cant internal development. However, they are less connected with other themes in
the research field because of their low centrality values (upper-left quadrant).
2.3.2. SMA for Social Framework
VOSviewer was used as previously described by Van Eck and Waltman [22]. VOSviewer
allows users to create scientific maps based on network data and exploring them. Its work-
flow consists of three steps.
First, VOSviewer defines a CM based on the times that any pair of items appear
together within the documental corpus. Second, the software applies an algorithm to
display a distance-map where each point represents an item in a space. Herein, the
VOSviewer uses the SMACOF algorithm to approximate actual Euclidean distances to an
ideal model [29]. Third, the maps obtained need to be translated, rotated, and reflected to
achieve consistent results.
In our analysis, institutions and countries were evaluated according to its bibliometric
coupling relation, that is, the existence of a common cited reference in their reference
list [30]. The number of documents published and the number of cites received for each
institution or country were employed as weights. Consequently, the final result was a map
where the distance between institutions and countries was proportional to its bibliometric
coupling relation, and the size of each label in the map was proportional to the number of
documents reported or citations received in the period evaluated.




A total of 525 documents were retrieved after performing the search strategy. The
journal article was the predominant type as it appeared up to 359 documents (68.38%
of the corpus), followed by 106 proceeding papers (20.19%), reviews (6.66%), and meet-
ing abstracts (6.28%) (Figure 1A). Furthermore, the growth of the field was particularly
remarkable from 2017 to present day (Figure 1B). Cumulative production can be ad-
justed to an exponential and potential model with a R2 = 0.9112 and 0.9733, respectively
(Figure 2A,B). Furthermore, a third-degree polynomic model defined by the equation
y = 0.0518x3 − 1.511x2 + 17.345x − 35.972 (R2 = 0.9701) predicted that literature would dou-
ble in 2027, and it would be three-fold the current number near 2031 (Figure 2C).
Figure 1. Evolution of documents referred to AI and ML applications to diagnostic pathology in
lymphoid neoplasms from 1990 to 2020. (A) Document production trends referred to AI and ML
applications to diagnostic pathology in lymphoid neoplasms according to document type (original
article, review, proceeding papers, and meeting abstracts) from 1990 to 2020. (B) Global production
trends of documents referred to AI and ML applications to the field of diagnostic pathology in
lymphoid neoplasms from 1990 to 2020.
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Figure 2. Cumulative journal production by year in the area of AI and ML applications to diagnostic pathology in lymphoid
neoplasms. (A) Adjustment to an exponential model. (B) Adjustment to a potential model. (C) Adjustment to a third degree
polynomic model. (D) Evolution of the five most developed research areas in terms of article production (computer science,
engineering, radiology nuclear medicine, biochemistry molecular biology, and oncology) from 1990 to 2020.
3.1.2. Research Areas
During the period analyzed, the research area that gathered most of documents
was computer science (CS) with up to 128 documents (24.38%), followed by engineering
(EN) with 89 documents (16.95%), radiology nuclear medicine (RNM) with 61 documents
(11.61%), biochemistry and molecular biology (BM) with 60 documents (11.43%), and
oncology (ON) with 54 documents (10.29%).
Figure 2D shows the evolution of the top five research areas. From 2002 to 2020, CS
was at the forefront of research, while ON and RNM increased their contribution to the
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area since 2008 to the present days. A general crescent trend was evident from 2014 to
today both for biomedicine research areas (ON, RNM, and BM) and bioinformatics areas
(CS and EN).
3.1.3. Organizations and Research Centers
Table 1 shows the classification of universities and research centers in terms of pub-
lications, divided for three subperiods: (1) 1990–2004, (2) 2005–2014, (3) 2015–2020, and
globally. Of the 207 documents signed by the 20 most productive institutions, 119 were
published in the last period. The University of Texas System (3.62%), the Institute National
de la Santé et de la Recherche (INSERM) (2.86%), and Harvard University (2.48%) led
global production. Thirteen of the twenty most productive institutions were located in
the USA.
The Assistance Publique Hopitaux Paris (APHP) (1.71%), the Centre National de la
Recherche Scientifique (CNRS) (1.71%), the Technical University of Munich (1.52%), and
the Goethe University of Frankfurt (1.33%) were highlighted within European centers.
Finally, the Asiatic contribution showed a crescent trend from the beginning of the study,
the Chinese Academy of Science (2.29%) being among the five most relevant centers
worldwide for the whole period evaluated.
3.1.4. Source Titles
A total of 397 scientific journals reported at least one of the 525 documents in the area.
However, up to 388 journals (96.47%) have published less than five documents, signifying
secondary sources. This pattern of scientific production was in accordance with Bradford’s
law of bibliographic scattering, which determines that the most of documents belong to
a reduced nuclei of core journals, being unproductive to extend literature search beyond
it [31].
Table 2 shows the classification of source titles for the period studied. Globally, the
most productive journals were Lectures Notes in Computer Science with up to 14 docu-
ments (2.67%), Blood with 12 documents (2.28%) and the European Journal of Nuclear
Medicine and Molecular Imaging (EJNMMI) with 10 documents (1.90%).
3.1.5. Country Distribution
For the whole period assessed, the USA was the leading producer, reporting up to
190 (36.19%) of all documents. Furthermore, People’s Republic of China with 72 documents
(13.71%), Germany with 44 documents (8.38%), India with 35 documents (6.66%), and
France with 31 documents (5.90%) were also highlighted as important countries in terms of
scientific production (Table 3). Noteworthy, People’s Republic of China and India increased
their contributions from 1.56% to 13.71%, and from 1.56% to 6.67%, respectively, during the
whole period analyzed.
Worldwide heterogeneity increased as times became nearer to present day, which
could be demonstrated by the fact that the number of nations producing more than five
documents was 3 (4.84%) in the period 1990–2005, 7 (11.29%) in the period 2006–2014, and
19 (30.65%) in the period 2015–2020.
3.2. SMA
3.2.1. SMA for Cognitive Framework
The cognitive framework of the field is shown in Figures 3 and 4. The strategic
diagrams show the distribution of themes in MT, BT, HDI, and ED, according to Callon´s
density and centrality. Furthermore, the numerical value inside each sphere indicates the
number of documents that employ this concept as keyword.
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Table 1. Analysis of documents referred to AI and ML applications to diagnostic pathology in lymphoid neoplasms by institutions from 1990 to 2020. Data are provided by subperiods
(1990–2005; 2006–2014; 2015–2020) and globally. C: document count; %: percentage of documents.
Institution 1990–2005 Institution 2006–2014 Institution 2015–2020 Institution TOTAL
C % C % C % C %
NAGOYA
UNIVERSITY 5 7.81 CORNELL UNIV 4 3.50 CHINESE ACAD SCI 10 2.87
UNIV OF TEXAS
SYSTEM 19 3.61
AICHI CANC CTR 4 6.25 INDIAN STAT INST 4 3.50 EMORY UNIV 10 2.87 INSERM 15 2.85
ST JOHNS HOSP 3 4.68 JADAVPUR UNIV 4 3.50 UNIV TEXAS MDANDERSON 8 2.29 HARVARD UNIV 13 2.47




7 2.01 UNIVCALIFORNIA SYSTEM 13 2.47
FLORIDA INT UNIV 2 3.12 NCI 3 2.63 UNIV PENN 7 2.01 CHINESE ACAD SCI 12 2.28
HARVARD UNIV 2 3.12 NIH 3 2.63 ICAHN SCH MED MTSINAI 6 1.72 CORNELL UNIV 12 2.28
NANYANG TECHNOL





OHIO STATE UNIV 2 3.12 TONGJI UNIV 3 2.63 TECH UNIVMUNICH 6 1.72 EMORY UNIV 10 1.90
THOMAS


















TECHNOL 5 1.43 APHP PARIS 9 1.71
UNIV ROMA LA
SAPIENZA 2 3.12 UNIV TURIN 3 2.63
MASSACHUSETTS
GEN HOSP 5 1.43
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Table 1. Cont.
Institution 1990–2005 Institution 2006–2014 Institution 2015–2020 Institution TOTAL








MOUNT SINAI 9 1.71
UNIV SO CALIF 2 3.12 CHARITE 2 1.75 OHIO STATE UNIV 5 1.43 NIH 9 1.71
UNIV TURIN 2 3.12 DANA FARBER CANCINST 2 1.75
SHANGAI JIAO TONG
UNIV 5 1.43 MAYO CLINIC 8 1.52
YONSEI UNIV 2 3.12 FLORIDA INT UNIV 2 1.75 SICHUAN UNIV 5 1.43 STATE UNIV SYSTEMOF FLORIDA 8 1.52




CTR 1 1.56 HARVARD UNIV 2 1.75 UNIV SYDNEY 5 1.43 YONSEI UNIV 8 1.52
CENTROL NACL





1 1.56 INDIAN INSTTECHNOL 2 1.75 CHB HOSP 4 1.14
GOETHE UNIV
FRANKFURT 7 1.33
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Table 2. Analysis of documents referred to AI and ML applications to diagnostic pathology in lymphoid neoplasms by source titles from 1990 to 2020. Data are provided for three
subperiods (1990–2005; 2006–2014; 2015–2020) and globally. Bold type indicates Bradford nuclei for the 25% of total production for each period. Source titles are abbreviated. C: document
count; %: percentage of documents.
Source Title 1990–2005 Source Title 2006–2014 Source Title 2015–2020 Source Title TOTAL




3 4.68 LECTURE NOTES INCOMPUTER SCIENCE 5 4.38
EUROP JOURN NUCL
MED MOL IMAG 10 2.87
LECTURE NOTES IN
COMPUTER SCIENCE 14 2.66
HUMAN PATHOLOGY 3 4.68 BMCBIOINFORMATICS 4 3.50 BLOOD 9 2.25 BLOOD 12 2.28
LECTURE NOTES IN




MED MOL IMAG 10 1.90
PROCEEDINGS OF

















2 3.12 BMC GENOMICS 2 1-75 LECTURE NOTES INCOMPUTER SCIENCE 6 1.72
BMC
BIOINFORMATICS 7 1.33

















2 1.75 IEEE ACCESS 5 1.43 JOURNAL OF NUCLEARMEDICINE 6 1.14
PROCEEDING OF THE
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Table 2. Cont.
Source Title 1990–2005 Source Title 2006–2014 Source Title 2015–2020 Source Title TOTAL








4 1.14 FRONTIERS IN ONCOLOY 5 0.95
2001 IEE NUCLEAR
SCIENCE SCR 1 1.56 2006 IEEE IJCNNP 1 0.87
BLOOD
ADVANCES 4 1.14 IEEE ACCESS 5 0.95





2005 27TH ANNUAL IC-IEE
E-EMBS
1 1.56 2008 INTERNATIONALSTCITAB 1 0.87 IEEE ICBB 4 1.14
LABORATORY
INVESTIGATION 5 0.95




















1 1.56 2010 7TH IEEE ISBINM 1 0.87 PLOS ONE 4 1.14 CANCERS 4 0.76
AMERICAN JOURNAL OF
DERMATOPATHOLOGY 1 1.56 2012 7




3 0.86 COMPUTERS IN BIOLOGYAND MEDICINE 4 0.76
AMERICAN JOURNAL OF
HEMATOLOGY 1 1.56 2012 9
TH IEEE ISBI 1 0.87
GENOME
MEDICINE 3 0.86 IEE ICBB 4 0.76
AMIA 2002 SYMPOSIUM
PROCEEDINGS 1 1.56 2013 12





3 0.86 LEUKEMIA 4 0.76
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Table 3. Analysis of documents referred to AI and ML applications to diagnostic pathology in lymphoid neoplasms by countries from 1990 to 2020. Data are provided for three subperiods
(1990–2005; 2006–2014; 2015–2020) and globally. C: document count; %: percentage of documents.
Country 1990–2005 Country 2006–2014 Country 2015–2020 Country TOTAL
C % C % C % C %
USA 25 39.06 USA 38 33.33 USA 127 36.49 USA 190 36.19
ENGLAND 6 9.37 PEOPLE’S R CHINA 14 12.28 PEOPLE’S R CHINA 57 16.37 PEOPLE’S R CHINA 72 13.71
GERMANY 6 9.37 INDIA 12 10.52 GERMANY 33 9.48 GERMANY 44 8.38
JAPAN 5 7.81 ENGLAND 11 9.64 FRANCE 23 6.60 INDIA 35 6.66
ITALY 4 6.25 ITALY 8 7.01 INDIA 22 6.32 FRANCE 31 5.90
CANADA 3 4.68 FRANCE 7 6.14 SPAIN 19 5.46 ENGLAND 30 5.71
IRELAND 3 4.68 JAPAN 6 5.26 ITALY 18 5.17 ITALY 30 5.71
SINGAPORE 3 4.68 GERMANY 5 4.38 AUSTRALIA 14 4.02 JAPAN 23 4,38
AUSTRALIA 2 3.12 IRAN 5 4.38 ENGLAND 13 3.73 SPAIN 23 4.38
NETHERLANDS 2 3.12 POLAND 4 3.50 JAPAN 12 3.44 AUSTRALIA 17 3.23
NEW ZEALAND 2 3.12 SINGAPORE 4 3.50 SOUTH KOREA 12 3.44 SOUTH KOREA 16 3.04
SOUTH KOREA 2 3.12 CROATIA 3 2.63 CANADA 10 2.87 CANADA 14 2.66
WALES 2 3.12 SPAIN 3 2.63 SWITZERLAND 10 2.87 NETHERLANDS 12 2.28
BARBADOS 1 1.56 AUSTRIA 2 1.75 NETHERLANDS 9 2.58 SWITZERLAND 12 2,28
CROATIA 1 1.56 BRAZIL 2 1.75 AUSTRIA 8 2.29 AUSTRIA 10 1.90
FRANCE 1 1.56 MEXICO 2 1.75 BRAZIL 8 2.29 BRAZIL 10 1.90
INDIA 1 1.56 SLOVENIA 2 1.75 DENMARK 8 2.29 IRAN 10 1.90
ISRAEL 1 1.56 SOUTH KOREA 2 1.75 SWEDEN 7 2.01 DENMARK 9 1.71
PEOPLES R CHINA 1 1.56 AUSTRALIA 1 9.87 SAUDI ARABIA 6 1.72 SINGAPORE 8 1.52
POLAND 1 1.56 BELGIUM 1 0.87 EGYPT 5 1.43 SWEDEN 8 1.52




Figure 3. Two-dimensional space layout of research themes on AI and ML applications to diagnostic pathology in lymphoid neoplasms according to Callon´s density (vertical axis) and
Callon´s centrality (horizontal axis) as shown by the SciMAT software. Research themes are categorized in Motor themes, Basic and Transversal themes, Emerging or Declining themes,
and Highly Developed themes. Some themes that recur over time have been marked in the same color (blue and green). (A) Strategic diagram of the cognitive framework for the period
1990 to 2005. (B) Strategic diagram of the cognitive framework for the period 2006 to 2014.







Figure 4. Two-dimensional space layout of research themes on AI and ML applications to diagnostic pathology in lymphoid
neoplasms according to Callon´s density (vertical axis) and Callon´s centrality (horizontal axis) as shown by the package
SciMAT. Strategic diagram of the cognitive framework for the period 2015–2020. Themes that recur over time have been marked
in the same color (blue). The dashed marks in green show clinical entities that have appeared in the last period, compared
to non-Hodgkin’s lymphomas in the previous diagrams, also shown in green with continuous lines. The second topic that
agglutinates a higher number of documents in the period 2015–2020 (lymphoma classification) has been highlighted in red.
As time approached the present, an increase in the number of terms linked to medical
practice took place. First, the ensemble classifier was the only MT identified in the first
period, while non-Hodgkin, machine learning, support vector machine, and subgroups
were identified as MT in the second period. Moreover, notions such as antitumor drug
design, resistance, and magnetic resonance were identified as MT in the last period.
In parallel, BT evolved from the notions of bioinformatics and support vector (period
1990–2005) to neural networks, mass spectrometry, antitumor drug design, and poor
prognosis (period 2006–2014). Finally, lymphoma classification, chronic lymphocytic
leukemia, Hodgkin lymphoma, and random forest were identified as BT in the period
2015–2020.
3.2.2. SMA for Social Framework
The relations among institutions are shown in Figures 5–7. Two different regions can be
observed: (1) a cluster of institutions sited in the USA, European centers, and some Asiatic
organizations, and (2) an area represented by the Chinese Academy of Science (Figure 5).
When citation counts were evaluated, the structure of the map did not change in terms of
institutions location; however, the role of Harvard University notably increased (Figure 6).









Figure 5. World map showing the structure of relations among research institutions as shown in the network visualization module of the VOSviewer software. The map shows the
bibliometric coupling relation among institutions according to the number of documents published for each institution.










Figure 6. World map showing the structure of relations among research institutions as shown in the network visualization module of the VOSviewer software. The map shows the
bibliometric coupling relation among institutions according to the number of citations received for each institution.







Figure 7. World map showing the structure of relations among countries as shown in the network visualization module of the VOSviewer software. (A) Map for the bibliometric coupling
relation among countries according to the number of documents published for each country. (B) Map for the bibliometric coupling relation among countries according to the number of
citations received for each country.
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The global distribution by countries is shown in Figure 7. On the one hand, the USA
and People’s Republic of China stood out when documental production was assessed
(Figure 7A). Moreover, England, Japan, and a network of European nations (Italy, Spain,
Germany, and France) collaborated with the USA, which acted as the central node of the
map. On the other hand, the analysis of citation impact revealed some variations, showing
a decrease in Asiatic contributions and a maintenance of the USA and England as the major
contributors of the area (Figure 7B).
4. Discussion
Human reasoning works by integrating new knowledge to previous experience. Thus,
it is limited by the volume of information it is able to store and manage. AI, as a computer
science aimed to design, develop, and validate devices capable of mimicking human
intelligence, has the potential to overcome that barrier. By extension, clinical and diagnostic
reasoning could be optimized through the incorporation of AI and ML tools to daily
practice in pathology departments.
In the omics era [32], the volumes of data generated by sequencing techniques have
led to new insights in the biology of hematological diseases [33], by revolutionizing how
clinicians approach diagnosis, prognosis, and make therapeutic decisions. In this sense,
research in hematopathology has been pioneering in the translation from bench to bed-
side [34], allowing for the clinical use of risk stratification models and targeted therapies,
based on genetic and molecular data [35,36].
The field of AI and ML applications to diagnostic pathology in LN constitutes an
active focus of research [14,15]. Specifically, digitalization of histopathological slides, and
the integration of genomic analysis oriented to optimize diagnostic platforms in LN is
at the forefront of research [37]. The development of AI/ML methods in other medical
disciplines such as oncology is also remarkable. In this sense, in colorectal cancer, some AI
algorithms have been developed to automatically discriminate between neoplastic regions
and non-tumorous tissue [38]. Using scanned preparations, tumor areas of pancreatic
neuroendocrine tumors can be delineated from the stroma using DL [38], which allows
better quantification of Ki67 in tumor areas only (97.8% sensitivity, 88.8% specificity) [39].
In breast cancer, it is possible to automatically pinpoint areas of intraductal carcinoma or in-
filtrating carcinoma on hematoxylin-eosin and classify the digital preparations as benign or
malignant, reaching an area under the curve (AUC) of 0.962 in digital preparations [38–40].
Of note, the first EU-approved DL system with CE-IVD marking (the official marking
required for the European Community) was for the detection of prostate cancer [35]. In
the literature, the efficacy in prostate cancer detection of DL systems is remarkably high
(using tissue arrays or TMA, prostate biopsies, and prostatectomies), with AUC values of
between 0.98 and 0.997 to classify prostate biopsies in benign or malignant [39,41].
However, the identification of the main global trends of AI applications to diagnostic
pathology in LN, prediction of future research avenues and definition of its cognitive and
social framework had not yet been performed. In this work, we analyzed the status of AI
and ML applications to diagnostic pathology in LN by means of bibliometric techniques
for a period between 1990 and 2020.
On the one hand, documental production experienced a marked increase, especially
since 2017. Based on the behavior of the research field studied, future production can be
predicted through a third-degree polynomic equation (y = 0.0518x3 − 1.511x2 + 17.345x
− 35.972) which established that literature would double in 2027, and would be three-
fold the current number near 2031. This prediction manifestly overwhelms Price´s law
of the growth of science, which postulates that publications double each 10–15 years,
approximately [42]. Biomedical literature usually does not fit in this model, because of its
high consumption and obsolescence rates. Moreover, the use of this equation for monitoring
future production should be interpreted cautiously. First, the mere fact of modeling the
evolution of science constitutes a challenging activity, as revolutionary ideas usually disrupt
the accumulative view of scientific evolution, leading to the emergence of new paradigms
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that change the way in which research activity is usually conducted, as demonstrated by
Kuhn [43]. Furthermore, the mathematical model has certain limitations. In this sense,
polynomial regression is a form of linear regression, and consequently the accuracy of
predictions, that is, the power of the model to assign a precise value to the dependent
variable (i.e., future research production), depends on the number of independent variables
included. Subsequently, as new data will be available, there will be the need to update this
model. In this sense, not only polynomic models, but ay regression model, will be affected
by the availability of new data and, thus, by time. However, the greater the number of
terms in the polynomial equation, the greater the accuracy of the model built to provide
valuable information. Regarding this, an interesting paper by Ostertagová revised the
strengths and drawbacks of the use of polynomial regression for modeling [44].
However, it can be affirmed that the optimization of subtyping in LN by explod-
ing computational analysis of large amounts of genomic information and its integration
within platforms of digital image will prominently increase in coming years. This novel
scenario will probably put the pathology departments and related colleagues in an un-
precedented setting, where basic concepts about bioinformatics and AI will be demanded
to professionals in order to achieve an expertise level, both in clinics and research arenas.
Moreover, obtained results about the scientific production in this research field can
also be inserted in a Gompertzian model, to better evaluate the current scientific scenario
of AI and ML applications to diagnostic pathology in LN [45]. In this way, three stages of
scientific evolution can be defined: (1) an initial phase where seminal papers of the area
were published, (2) an intermediate phase where an exponential growth of literature occurs
leading to the forefront of research, and (3) a last phase characterized by the storage of
knowledge by means of reviews and, thus, the consolidation of the field.
Probably, as it can be deduced from Figure 1B, the area of AI and ML applications to
diagnostic pathology in LN remains in a transition stage between the second and third
phases. It is worthy to note that the rate of document production has been under an
exponential model since 2012 (Figure 2A) and, interestingly, the publication of reviews
(an early sign of information synthesis) is increasing since 2015 (Figure 1A). Thus, from a
global bibliometric perspective, it can be hypothesized that this research field is not in an
emerging phase, but rather, its consolidation constitutes an ongoing process.
Globally, most of the documents belong to the area of CS. Nevertheless, RNM has
become a major focus of research in recent years. Of note, the integration of molecular
imaging and AI algorithms will, probably, constitute an essential pillar in LN management
in the near future, not only with diagnostic and staging purposes, but also as a prognostic
marker. Regarding this, several AI algorithms have been tested for this purpose, such as
deep learning (DL) for the reconstruction of positron emission tomography (PET) image in
Hodgkin lymphoma (HL) [46], convolutional neural networks (CNNs) for the prediction
of diffuse large B-cell lymphoma (DLBCL) total metabolic tumor based on PET/computed
tomography (CT) [47] and support vector machine (SVM) to discriminate hypermetabolic
lymphomatous lesions and noncancerous processes [48].
On the other hand, the analysis of source titles shows that three journals, Lecture
Notes in Computer Science, Blood, and the EJNMMI, were the most productive journals
in the area. In this sense, as there is not a unique bibliographic database covering the
whole scientific production in any area, continuous monitoring and updating of the content
included in the different available databases are of paramount importance to precisely
characterize the scenario where scientific research takes place. In this study, we have used
WoS as it constitutes the standard database in bibliometric studies for identifying and
monitoring research trends [49]. WoS provides information for more than 250 disciplines,
21,000 scientific journals, and 1.6 billion of cited references from 1900 to the present [24].
However, the list of source titles showed in this work and, hence, the classification of
journals could vary if a different bibliographic database is consulted. As a consequence,
these results should be interpreted with caution and tacking into consideration the complex
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process of indexing journal information and bibliometric indicators into the different
available bibliographic databases.
Furthermore, our results are in concordance with Bradford’s law of scattering as a
minority of sources are responsible for the most of scientific production [28]; in fact, up to
388 journals (96.47%) published less than five documents during the whole period studied.
Similar patterns have been demonstrated in other growing areas in biomedicine such as
medical advanced therapies [50]. In our study, 103 from the 128 documents retrieved were
published in the last period, proving the important editorial effort made in recent years.
Regarding this, relevant journals in the area such as Leukemia, Frontiers in Oncology, and
the American Journal of Clinical Pathology appeared in the top 20 of source titles.
In terms of contributions, the USA (36.90%), People’s Republic of China (13.71%),
Germany (8.38%), India (6.67%), and France (5.91%) were at the front of the research.
Among the top five centers worldwide, three of them are located in the USA (University of
Texas System, Harvard University, and University of California System), and the INSERM
and the Chinese Academy of Sciences were highlighted among European and Asiatic
centers, respectively. In this context, the evolution of the People’s Republic of China is
remarkable as it has increased its contributions from 1.56% in the first period to 13.71%
in the last period, also suggesting an important increase in financial investment in the
research area.
Furthermore, we also performed SMA of the field in order to elucidate its cognitive
and social framework [51]. Regarding this, several SMA tools have been developed and
validated to analyze collaboration patterns among institutions [24,52] , identify growing
scientific areas of interest [53] and optimize funding allocation in scientific research [54].
Here, we have used the software SciMAT and VOSviewer, because of their proven quality
to perform both conceptual and social evaluation on biomedicine related disciplines [21,22].
First, the cognitive framework of AI and ML applications to diagnostic pathology
in LN showed a crescent clinical application of these tools. Interestingly, the ensemble
classifier was the only MT identified in the first period. Briefly, EC methods compensate
partial errors by introducing the output of one base model as the input for the next
algorithm in the sequence, thus, improving the average prediction power [55]. Interestingly,
a previous study used this approach to predict mortality after hematopoietic stem cell
transplantation (HSCT) [56].
In recent years, most research has been focused on lymphoma subtyping by integrating
different AI algorithms. On the one hand, ML, neural networks (NNs), and SVM appeared
as MT and BT in the second and third periods, respectively. On the other hand, lymphoma
classification was among the most developed concepts in the last period. Specifically, the
integration of digital image analysis and genomic sequencing by means of different AI
algorithms in non-Hodgkin lymphoma (NHL) constitutes a major topic of research in this
area. In this way, logistic regression and Cox proportional hazards have been employed for
building a cell-of-origin (COO) classifier in DLBCL based on targeted RNA sequencing
(RNA-seq) data [20]. Gene expression profiling (GEP) of 414 DLBCL patients treated with
CHOP/R-CHOP were used as inputs for a SVM model which accurately stratified them
in two biologically distinct subgroups [57]. Furthermore, a random forest algorithm was
trained and validated to discriminate the most frequent B-cell NHL categories among
510 cases of NHL, based on ligation-dependent RT-PCR and next-generation sequencing
(NGS) [16].
Moreover, immunophenotyping, either by flow cytometry [58] or immunohistochem-
istry [59], has been also employed to train AI models for the diagnosis of B-cell NHL. A
CNN algorithm was developed based on digital histopathological slides using Aperio
ImageScope (Leica Biosystems, Buffalo Grove, IL) to discriminate between Burkitt lym-
phoma (BL) and DLBCL [60], and interesting approaches grounded on fuzzy logics have
demonstrated high accuracy to subclassify DLBCL based on transcriptional profiling data
obtained from “lymphochip” DNA microarrays [61].
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Drug discovery and prediction of response were also identified as relevant topics
in this area. Regarding this, the notion of sensitivity constituted an HDI during the
first and second periods, likely accounting for a pre-clinical application of ML to drug
evaluation, while antitumor drug design was the most developed concept in the last period.
Interestingly, since the original description of DL in drug discovery [62], there have been
considerable efforts to expand these kinds of AI applications within hematopathology
research. In this setting, Turki et al. developed a transfer learning algorithm to predict
sensitivity to Bortezomib in multiple myeloma [63], and a model based on Bayesian
network and NNs, combined with RNA-seq, has identified novel mechanisms of resistance
in 150 drugs evaluated in DLBCL [64]. Thus, the advent of powerful ML approaches
also has the potential to open new horizons in drug evaluation and pharmacogenomic
areas [65].
As mentioned, when analyzing research areas and source titles, functional imaging
analysis and AI constitutes a growing area of interest. Regarding this, it could be defined
a cognitive evolution from general concepts such as medical image analysis (first and
second periods) to more specific tools such as magnetic resonance and CT. Herein, deep
CNNs have been employed to discriminate patterns of tumor infiltration in PET/CT in
327 patients with NHL [66], and prediction of response to conventional chemotherapy
by integrating AI and molecular techniques also constitutes a growing area of interest in
recent years [47,67].
In addition, the cognitive evaluation of the field also leads to the identification of
particular hematological disorders in which applications of AI and ML are being carried
out, such as chronic lymphocytic leukemia (CLL) and Hodgkin lymphoma (HL). Although
NHL accounts for the most of research conducted during the whole period, here we also
reported ML approaches to identify CLL patients at high risk of infection [68] and to
optimize CLL diagnosis through GEP and artificial NNs (ANNs) [69]. In relation to AI and
ML applications to the diagnosis of HL, the complexity to adequately isolate Hodgkin and
Reed–Stenberg (HRS) cells within a major non-tumoral microenvironment can be under
the relative absence of AI applications for this entity. However, stimulating works have
proved the potential of ML algorithms to predict prognosis in HL, both in adults [70] and
pediatric patients [71].
To better comprehend the structure of this research field, we also evaluated its social
framework by means of the software VOSviewer [22]. First, the role of the USA in the
development of the area was highlighted both in terms of scientific contributions and
citation impact. As depicted in Figure 5, two major nodes of production were identified.
On the one hand, there was a cluster of organizations mainly located in the USA and
Europe, which also collaborate with certain Asiatic centers (Shanghai Jiao Tong University,
Tongji University, Yonsei University, Sichuan University). On the other hand, the Chinese
Academy of Sciences appeared relatively isolated towards the periphery of the map.
Obtained results can be explained in terms of different patterns of collaboration,
where European and USA institutions tend to a more collaborative trend, while Asiatic
centers conduct a more unified research strategy. However, this hypothesis requires
more in-depth studies to evaluate the particular structure of each country in terms of
scientific investment and science promotion policies. Additionally, when citation impact
was assessed, institutions cited in the USA, such as Harvard University, appeared as
relevant centers within the map.
In summary, the results of this study show an important increase in scientific produc-
tion and predict a more accelerated growth over the next 10 years in the field of AI and
ML applications to diagnostic pathology in LN. Moreover, the integration of genomic and
molecular data with digital image analysis through different AI algorithms will probably
constitute an important pilar in the future practice within pathology departments, both
to optimize diagnostic and prognostic procedures. In this sense, a better comprehension
of the social and cognitive structure of the area can also serve to public institutions and
administrations to optimize funding allocation, identify areas of growing interest, and
Biomolecules 2021, 11, 793 21 of 24
promote synergies among clinical and research centers, which is an unavoidable condition
for the right progress of hematopathology.
5. Conclusions
The use of AI and ML tools in diagnostic hematopathology is increasing over time, as
demonstrated by the crescent trends reported in the literature. On the one hand, most of
the research has been focused on the study of non-Hodgkin´s lymphomas in particular,
in the analysis of genomic data for improving lymphoma classification, digitalization of
histopathological slides, and medical image analysis. On the other hand, different research
centers located mostly in Europe and USA highlighted in the social analysis of the research
field. Finally, although the results of this work show a growing trend in research and
publications on AI applications in the evaluation of LN, the full clinical implementation
of these systems in the future will require the training and development of collaborative
programs between pathologists, bioinformaticians and clinicians.
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